Prolonged zoledronic acid-induced hypocalcemia in hypercalcemia of malignancy

Article Type

Changed

Thu, 12/15/2022 - 18:02

Display Headline

Author(s)

Zoledronic acid is a parenteral long-acting bisphosphonate that has been shown to be more efective than other bisphosphonates in treating hypercalcemia of malignancy. It is important to be aware of its ability to induce prolonged and severe hypocalcemia (hypoCa) following administration, which can be difficult to control despite aggressive calcium replacement. We report on a patient with metastatic breast cancer who presented with severe symptomatic hypoCa after receiving zoledronic acid for hypercalcemia of malignancy.

Click on the PDF icon at the top of this introduction to read the full article.

Article PDF

JCSO_oct_374_Narechania.pdf

Issue

The Journal of Community and Supportive Oncology - 13(10)

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology

Breast Cancer ICYMI

Topics

Breast Cancer

Patient & Survivor Care

Page Number

374-377

Legacy Keywords

zoledronic acid, hypocalcemia, hyercalcemia

Sections

Case Reports

Author(s)

Shraddha Narechania et al

Author(s)

Shraddha Narechania et al

Article PDF

JCSO_oct_374_Narechania.pdf

Article PDF

JCSO_oct_374_Narechania.pdf

Zoledronic acid is a parenteral long-acting bisphosphonate that has been shown to be more efective than other bisphosphonates in treating hypercalcemia of malignancy. It is important to be aware of its ability to induce prolonged and severe hypocalcemia (hypoCa) following administration, which can be difficult to control despite aggressive calcium replacement. We report on a patient with metastatic breast cancer who presented with severe symptomatic hypoCa after receiving zoledronic acid for hypercalcemia of malignancy.

Click on the PDF icon at the top of this introduction to read the full article.

Zoledronic acid is a parenteral long-acting bisphosphonate that has been shown to be more efective than other bisphosphonates in treating hypercalcemia of malignancy. It is important to be aware of its ability to induce prolonged and severe hypocalcemia (hypoCa) following administration, which can be difficult to control despite aggressive calcium replacement. We report on a patient with metastatic breast cancer who presented with severe symptomatic hypoCa after receiving zoledronic acid for hypercalcemia of malignancy.

Click on the PDF icon at the top of this introduction to read the full article.

Issue

The Journal of Community and Supportive Oncology - 13(10)

Issue

The Journal of Community and Supportive Oncology - 13(10)

Page Number

374-377

Page Number

374-377

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology